Announced Mon, 3 Aug · 08:21 IST
Biocon launches Yesafili biosimilar to Eylea in the US market
Regulatory Product ApprovalExport Order Hard CurrencyBusiness Updates View source PDFExplain this filing
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹426.00
prior close
₹429.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.1-1.0-0.8-0.5-0.2-0.2+2.5+0.1+0.0+0.3————
Up moveDown movePending
AI summary
Biocon has commercially launched Yesafili (aflibercept-jbvf), a biosimilar to Regeneron's Eylea 2 mg, in the United States on August 3, 2026. The product is a US FDA-approved interchangeable biosimilar for treating eye conditions like wet AMD. The US aflibercept market was around $5.89 billion in 2023, with about 19.8 million Americans affected by AMD. This marks Biocon's entry into the US ophthalmology biosimilars market.
Likely market impact
Strengthens Biocon's US presence in ophthalmology biosimilars. Access to a $5.89 billion US market could boost long-term revenue.